In the USA,
psoriasis affects approximately 3% of the population and costs more than $110 billion annually. The development of targeted biologics has revolutionized
psoriasis management, but at an increasing cost. According to Joint AAD/NPF guidelines, an important need exists to identify
biomarkers that can predict the appropriate
biologic agent for patients.
METHODS: Respondents confirmed that trial and error leads to frequent
biologic switching. The survey indicated that 82% of dermatologists switch 10-30% of their patients in the first year and 98% switch intra-class for at least 50% of non-responding patients. The trial and error is due, in part, to formularies influencing the physician 77% of the time, with only 14% reporting that their first choice and the formulary alignment is greater than 75%. Compounding trial and error, 93% of the physicians report that they wait at least 12 weeks before determining non-response, in alignment with AAD/NPF guidelines. The lack of
precision medicine and this trial-and-error approach result in unnecessary wasted spending and suboptimal patient outcomes. After being given an overview of Mind.Px, a dermal
biomarker patch used to predict therapeutic response to a
biologic class, survey participants expressed that: 93% would utilize Mind.Px results to determine first-line
therapy even if this differed from initial clinical choice 100% would utilize Mind.Px if part of the prior authorization process 98% say Mind.Px would improve patient outcomes 81% reported Mind.Px would help with prior authorization process CONCLUSIONS: Surveyed dermatologists believe a test that predicts
psoriasis treatment response to a class of
biologic drugs would lessen trial and error, provide a tool for physicians to make more informed decisions about
drug selection, improve patient outcomes, and significantly reduce wasted spending.